WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.

Corticosteroids for systemic use, see H02.


L03 IMMUNOSTIMULANTS

Immunosuppressants, see L04A.


L03A IMMUNOSTIMULANTS

Levamisole, which also affects the immune response, is classified in P02CE.


L03AA Colony stimulating factors

The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.

L03AB Interferons

Peginterferon alfa-2b in combination with ribavirin and peginterferon alfa-2a in combination with ribavirin are classified in L03AB60 and L03AB61, respectively.

The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.

The DDDs of interferon beta-1a is based on i.m. administration.

L03AC Interleukins

The DDD for aldesleukin is based on the use of 5 vials (6.5 mg) per treatment cycle of 33 days.

L03AX Other immunostimulants

The DDD for tasonermin is based on single dose treatment.

The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).

Last updated: 2018-12-13